<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7476961\results\search\drug\results.xml">
  <result pre="RNA genome into the cytoplasm (endocytic pathway). Alternatively, Transmembrane Protease" exact="Serine" post="type 2 (TMPRSS2) is also involved in priming of"/>
  <result pre="the inhibitory potential of EK1C, further derivatives were designed with" exact="glycine" post="/ serine-based linkers (GSG) and PEG-based spacers. The peptides"/>
  <result pre="and was blocked by a clinically known inhibitor of TMRSS2," exact="camostat" post="[33]. Hence, TMPRSS2 based therapeutics could prove to be"/>
  <result pre="to SARS CoV-2 nsp12, was investigated based on modeling with" exact="sofosbuvir" post="bound to hepatitis C virus (HCV) ns5b. The nsp12"/>
  <result pre="polymerase and selectively binding catalytic site of the HCV polymerase." exact="Sofosbuvir" post="has been approved for the treatment of chronic HCV"/>
  <result pre="Fintelman-Rodrigues and co-workers shed light on the promising potential of" exact="atazanavir" post="and atazanavir/ritonavir combination for the treatment of COVID-19 [76]."/>
  <result pre="[76]. Through a combination of molecular docking and molecular dynamics," exact="atazanavir" post="was shown to bind to the active site of"/>
  <result pre="was also shown to inhibit the enzyme through zymographic studies." exact="Atazanavir" post="and atazanavir/ritonavir combination were evaluated for their inhibitory potential"/>
  <result pre="in both the cell lines potently. The EC50 values of" exact="atazanavir" post="and atazanavir/ritonavir combination against SARS-CoV-2 in Vero E6 cells"/>
  <result pre="and A549 cells are shown in Fig. 16 . Furthermore," exact="atazanavir" post="and atazanavir/ritonavir also prevented pro-inflammatory cytokine production in monocytes"/>
  <result pre="lactate dehydrogenase (LDH) and Interleukin-6 (IL-6). Fig. 16 Structure of" exact="atazanavir" post="and ritonavir. 2.6 Papain like protease (PLpro) Papain like"/>
  <result pre="screened it against a library of 2525 FDA approved drugs." exact="Praziquantel" post="(anti-parasitic), cinacalcet (anti-hyperparathyroidism), procainamide (anti-arrhythmic), terbinafine (antifungal) and pethidine"/>
  <result pre="library of 2525 FDA approved drugs. Praziquantel (anti-parasitic), cinacalcet (anti-hyperparathyroidism)," exact="procainamide" post="(anti-arrhythmic), terbinafine (antifungal) and pethidine (opioid analgesic) were identified"/>
  <result pre="17 ). No major adverse effects have been reported for" exact="praziquantel" post="and cinacalcet. However, procainamide, terbinafine, and pethidine have major"/>
  <result pre="for COVID-19 3.1 Antivirals 3.1.1 Remdesivir Remdesivir, a prodrug of" exact="adenosine" post="analog GS-441524 (Fig. 18 ), is an investigational antiviral"/>
  <result pre="18), it incorporates into the RNA strand after fending off" exact="Adenosine" post="triphosphate (ATP), the natural nucleotide incorporated in this process"/>
  <result pre="RNA synthesis [85], [86], [95] 3.1.2 Lopinavir/ritonavir combination Lopinavir and" exact="ritonavir" post="are two structurally related protease inhibitors that were developed"/>
  <result pre="due to metabolic inactivation by cytochrome P-450 (CYP) enzymes [96]." exact="Ritonavir" post="inhibits cytochrome P-450-3A4 (CYP3A4) at sub-therapeutic levels and hence"/>
  <result pre="(CYP3A4) at sub-therapeutic levels and hence is always co-administered with" exact="lopinavir" post="to prevent its metabolic degradation [97]. Lopinavir was found"/>
  <result pre="against SARS-CoV-2. A study on analysis of molecular complexation between" exact="lopinavir" post="and ritonavir with SARS-CoV-2 3CLpro suggested interaction of these"/>
  <result pre="A study on analysis of molecular complexation between lopinavir and" exact="ritonavir" post="with SARS-CoV-2 3CLpro suggested interaction of these drugs with"/>
  <result pre="the appropriate doses and course of treatment for COVID-19. 3.1.4" exact="Ribavirin" post="Ribavirin, a guanosine analog, has been used for the"/>
  <result pre="active metabolite [110]. Past studies have highlighted the combination of" exact="ribavirin" post="and interferon therapy as an effective treatment strategy for"/>
  <result pre="[112], [113]. Recently, Wang et al. highlighted the potential of" exact="ribavirin" post="to inhibit SARS-CoV-2 in vitro in Vero E6 cells"/>
  <result pre="ÂµM). Clinical trials are underway to evaluate the efficacy of" exact="ribavirin" post="in the treatment of COVID-19 [62]. 3.1.5 Other antiviral"/>
  <result pre="a protease inhibitor approved for the treatment of HIV, and" exact="cobicistat" post="prevents the catabolism of darunavir [116]. Clinical trials are"/>
  <result pre="further evidence is required to support such a claim. 3.2.2" exact="Azithromycin" post="Azithromycin is a broad-spectrum antibiotic that is used for"/>
  <result pre="evidence is required to support such a claim. 3.2.2 Azithromycin" exact="Azithromycin" post="is a broad-spectrum antibiotic that is used for the"/>
  <result pre="). A recently conducted clinical trial highlighted the importance of" exact="azithromycin" post="for the management of SARS-CoV-2 infection [117]. A total"/>
  <result pre="received chloroquine, and 16 patients served as control. Among the" exact="chloroquine" post="treated patients, six patients received azithromycin as a precautionary"/>
  <result pre="as control. Among the chloroquine treated patients, six patients received" exact="azithromycin" post="as a precautionary measure against bacterial superinfection. At the"/>
  <result pre="end of day 6, 100% of the patients treated with" exact="chloroquine" post="and azithromycin were cured off the virus while only"/>
  <result pre="day 6, 100% of the patients treated with chloroquine and" exact="azithromycin" post="were cured off the virus while only 57.1% of"/>
  <result pre="while only 57.1% of the patients were cured who received" exact="chloroquine" post="alone (negative PCR results). These outcomes should be further"/>
  <result pre="results). These outcomes should be further dwelled on to consider" exact="azithromycin" post="as viable adjuvant therapy for SARS-CoV-2 infection. Fascinatingly, azithromycin"/>
  <result pre="consider azithromycin as viable adjuvant therapy for SARS-CoV-2 infection. Fascinatingly," exact="azithromycin" post="has been reported to be active against other RNA"/>
  <result pre="mechanism of action of this drug. 3.3 Antiprotozoal drugs 3.3.1" exact="Chloroquine" post="and hydroxychloroquine Chloroquine and hydroxychloroquine belonging to the class"/>
  <result pre="action of this drug. 3.3 Antiprotozoal drugs 3.3.1 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine and hydroxychloroquine belonging to the class of 4-aminoquinolines"/>
  <result pre="of this drug. 3.3 Antiprotozoal drugs 3.3.1 Chloroquine and hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine belonging to the class of 4-aminoquinolines are"/>
  <result pre="drug. 3.3 Antiprotozoal drugs 3.3.1 Chloroquine and hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="belonging to the class of 4-aminoquinolines are primarily used"/>
  <result pre="the class of 4-aminoquinolines are primarily used as antimalarials. Structurally," exact="hydroxychloroquine" post="differs from chloroquine by the presence of one extra"/>
  <result pre="4-aminoquinolines are primarily used as antimalarials. Structurally, hydroxychloroquine differs from" exact="chloroquine" post="by the presence of one extra hydroxyl group. Besides"/>
  <result pre="presence of one extra hydroxyl group. Besides its antimalarial prowess," exact="chloroquine" post="has established itself as a broad-spectrum antiviral agent exhibiting"/>
  <result pre="DNA and RNA viruses [120], [121], [122], [123]. Concerning coronaviruses," exact="chloroquine" post="has been reported to be potent against the SARS-CoV-1"/>
  <result pre="Wang et al. shed light on the antiviral prowess of" exact="chloroquine" post="against the SARS-CoV-2. Chloroquine effectively blocked the viral infection"/>
  <result pre="light on the antiviral prowess of chloroquine against the SARS-CoV-2." exact="Chloroquine" post="effectively blocked the viral infection with a high selectivity"/>
  <result pre="[62]. Gao et al., in a recent publication, disclosed that" exact="chloroquine" post="treatment offered superior efficacy than control treatment in a"/>
  <result pre="patients [125]. Now answering the elephant in the room- Can" exact="hydroxychloroquine" post="also be used for the treatment of Covid-19? A"/>
  <result pre="for the treatment of Covid-19? A recent report demonstrated that" exact="hydroxychloroquine" post="is also effective against the SARS-CoV-2, and a study"/>
  <result pre="effective against the SARS-CoV-2, and a study also highlighted that" exact="hydroxychloroquine" post="is more potent against SARS-CoV-2 than chloroquine [126], [127]."/>
  <result pre="also highlighted that hydroxychloroquine is more potent against SARS-CoV-2 than" exact="chloroquine" post="[126], [127]. More arguments favor the use of hydroxychloroquine"/>
  <result pre="than chloroquine [126], [127]. More arguments favor the use of" exact="hydroxychloroquine" post="over chloroquine. Firstly, the presence of an extra hydroxyl"/>
  <result pre="clearance lessening the risk of retinal toxicity than chloroquine. Secondly," exact="hydroxychloroquine" post="is a safer option than chloroquine with respect to"/>
  <result pre="toxicity than chloroquine. Secondly, hydroxychloroquine is a safer option than" exact="chloroquine" post="with respect to therapeutic window and safety margins. Thirdly,"/>
  <result pre="and safety margins. Thirdly, owing to its proven immunomodulatory properties," exact="hydroxychloroquine" post="can act as an ideal treatment intervention in severely"/>
  <result pre="[128]. Recently, a controversial observational study on the effectiveness of" exact="chloroquine" post="or hydroxychloroquine with or without a macrolide for the"/>
  <result pre="a controversial observational study on the effectiveness of chloroquine or" exact="hydroxychloroquine" post="with or without a macrolide for the treatment of"/>
  <result pre="data from over 600 hospitals in six continents concluded that" exact="chloroquine" post="or hydroxychloroquine treatment afforded no protection to COVID-19 patients"/>
  <result pre="over 600 hospitals in six continents concluded that chloroquine or" exact="hydroxychloroquine" post="treatment afforded no protection to COVID-19 patients and was"/>
  <result pre="clinical trials like solidarity trials, RECOVERY trials have demonstrated that" exact="hydroxychloroquine" post="offers no benefit to COVID-19 patients [130], [131]. USFDA"/>
  <result pre="[131]. USFDA has also withdrawn its EUA status given to" exact="chloroquine" post="and hydroxychloroquine in view of the recent developments [132]."/>
  <result pre="has also withdrawn its EUA status given to chloroquine and" exact="hydroxychloroquine" post="in view of the recent developments [132]. 3.3.1.1 Mechanism"/>
  <result pre="of the recent developments [132]. 3.3.1.1 Mechanism of action of" exact="chloroquine" post="Chloroquine is claimed to act via two mechanisms. Chloroquine,"/>
  <result pre="the recent developments [132]. 3.3.1.1 Mechanism of action of chloroquine" exact="Chloroquine" post="is claimed to act via two mechanisms. Chloroquine, in"/>
  <result pre="of endosomal-lysosomal enzymes. By raising the pH of the vesicles," exact="chloroquine" post="can effectively inhibit the entry and replication process [133]."/>
  <result pre="chloroquine can effectively inhibit the entry and replication process [133]." exact="Chloroquine" post="indirectly interferes with the interaction between the SARS-CoV-1 spike"/>
  <result pre="protein is necessary for the viral entry into the cell." exact="Chloroquine" post="impairs the Golgi mediated N-terminal glycosylation of ACE-2, which"/>
  <result pre="the replication of SARS-CoV-2 in vitro[139]. A single treatment of" exact="ivermectin" post="at the dose of 5Â ÂµM resulted in an"/>
  <result pre="about 5000-fold reduction in viral titers following 48Â h of" exact="ivermectin" post="treatment. The safety profile of ivermectin is well established,"/>
  <result pre="following 48Â h of ivermectin treatment. The safety profile of" exact="ivermectin" post="is well established, and hence ivermectin can be potentially"/>
  <result pre="The safety profile of ivermectin is well established, and hence" exact="ivermectin" post="can be potentially repurposed against COVID-19. Fig. 21 Antiprotozoal"/>
  <result pre="by inhibiting TMPRSS2 [33]. Having already established its safety profile," exact="camostat" post="might prove to be a valuable drug in the"/>
  <result pre="to prove its efficacy for the treatment of COVID-19. 3.4.2" exact="Nafamostat" post="Following the footsteps of camostat is nafamostat (Fig. 22"/>
  <result pre="the treatment of COVID-19. 3.4.2 Nafamostat Following the footsteps of" exact="camostat" post="is nafamostat (Fig. 22 ), a serine protease inhibitor"/>
  <result pre="of COVID-19. 3.4.2 Nafamostat Following the footsteps of camostat is" exact="nafamostat" post="(Fig. 22 ), a serine protease inhibitor used as"/>
  <result pre="), a serine protease inhibitor used as an anticoagulant [140]." exact="Nafamostat" post="has been shown to inhibit the entry of MERS-CoV"/>
  <result pre="the entry of MERS-CoV by inhibiting cellular TMPRSS2 [141]. Recently," exact="nafamostat" post="was also shown to inhibit the novel SARS-CoV-2 in"/>
  <result pre="of Medical Science, the University of Tokyo, have disclosed that" exact="nafamostat" post="prevents the entry of novel SARS-CoV-2 by potently binding"/>
  <result pre="novel SARS-CoV-2 by potently binding to the transmembrane protease TMPRSS2." exact="Nafamostat" post="was able to achieve the fusion inhibition at less"/>
  <result pre="inhibition at less than one-tenth of the concentration required by" exact="camostat" post="[142]. Nafamostat can also be repurposed for therapeutic utility"/>
  <result pre="less than one-tenth of the concentration required by camostat [142]." exact="Nafamostat" post="can also be repurposed for therapeutic utility against COVID-19."/>
  <result pre="repurposed for therapeutic utility against COVID-19. Fig. 22 Fusion inhibitors-" exact="camostat" post="and nafamostat. 3.5 Immunomodulators and anti-inflammatory drugs A coordinated"/>
  <result pre="a clinical trial is underway to evaluate the efficacy of" exact="dexamethasone" post="in patients with ARDS secondary to SARS-CoV-2 infection (NCT04325061)."/>
  <result pre="RdRp inhibitor Teratogenic Phase 3 clinical trials (NCT04336904) [62], [164]" exact="Ribavirin" post="Antiviral 106.5 RdRp inhibitor Teratogenic, hemolytic anemia Phase 3"/>
  <result pre="available on the adverse effects associated with teicoplanin â€&quot; [47]" exact="Azithromycin" post="Antibiotic â€&quot; â€&quot; QT interval prolongation, severe hypersensitivity reactions"/>
  <result pre="data is available on Carrimycin Phase 4 clinical trial (NCT04286503)" exact="Chloroquine" post="Antiprotozoal 1.13 Raises the pH in the endocytic vesicles,"/>
  <result pre="hypoglycemia, neuropsychiatric effects Phase 3 clinical trial (NCT04303507) [62], [170]" exact="Hydroxychloroquine" post="Antiprotozoal 0.72 Raises the pH in the endocytic vesicles,"/>
  <result pre="available on the adverse events Phase 2 clinical trial (NCT04374019)" exact="Nafamostat" post="Anticoagulant 22.5 TMPRSS2 inhibitor Hyperkalemia, agranulocytosis, anaphylaxis Phase 2"/>
  <result pre="61ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug discovery and therapeutic optionsNat. Rev. Drug Discov.15201632734710.1038/nrd.2015.3726868298 62WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="designJ. Virol.8220082515252710.1128/jvi.02114-0718094151 73E. Lynch, J. Kil, Development of ebselen, a" exact="glutathione" post="peroxidase mimic, for the prevention and treatment of noise-induced"/>
  <result pre="N. Carels, C.R. Alves, M.M. Siqueira, P.T. Bozza, T.M.L. Souza," exact="Atazanavir" post="inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production, BioRxiv. (2020)"/>
  <result pre="marmosetJ. Infect. Dis.21220151904191310.1093/infdis/jiv39226198719 100NukoolkarnV.LeeV.S.MalaisreeM.AruksakulwongO.HannongbuaS.Molecular dynamic simulations analysis of ritronavir and" exact="lopinavir" post="as SARS-CoV 3CLpro inhibitorsJ. Theor. Biol.254200886186710.1016/j.jtbi.2008.07.03018706430 101NuthoB.MahalapbutrP.HengphasatpornK.PattaranggoonN.C.SimanonN.ShigetaY.HannongbuaS.RungrotmongkolT.Why are lopinavir"/>
  <result pre="and lopinavir as SARS-CoV 3CLpro inhibitorsJ. Theor. Biol.254200886186710.1016/j.jtbi.2008.07.03018706430 101NuthoB.MahalapbutrP.HengphasatpornK.PattaranggoonN.C.SimanonN.ShigetaY.HannongbuaS.RungrotmongkolT.Why are" exact="lopinavir" post="and ritonavir effective against the newly emerged Coronavirus 2019?:"/>
  <result pre="as SARS-CoV 3CLpro inhibitorsJ. Theor. Biol.254200886186710.1016/j.jtbi.2008.07.03018706430 101NuthoB.MahalapbutrP.HengphasatpornK.PattaranggoonN.C.SimanonN.ShigetaY.HannongbuaS.RungrotmongkolT.Why are lopinavir and" exact="ritonavir" post="effective against the newly emerged Coronavirus 2019?: Atomistic insights"/>
  <result pre="trials for 2019-nCoV infectionClin. Pharmacol. Ther.202010.1002/cpt.1844 110GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.162006374810.1002/rmv.48316287208 111FalzaranoD.De WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.BriningD.BushmakerT.MartellaroC.BaselerL.BeneckeA.G.KatzeM.G.MunsterV.J.FeldmannH.Treatment with interferon-Î±2b"/>
  <result pre="against distinct virusesRev. Med. Virol.162006374810.1002/rmv.48316287208 111FalzaranoD.De WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.BriningD.BushmakerT.MartellaroC.BaselerL.BeneckeA.G.KatzeM.G.MunsterV.J.FeldmannH.Treatment with interferon-Î±2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat. Med.1920131313131710.1038/nm.336224013700 112OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and"/>
  <result pre="high genetic barrier to resistanceExpert Opin. Pharmacother.1620152689270210.1517/14656566.2015.110963226612518 117GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontT.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="agent, inhibits zika virus infection in different cell modelsViruses8201610.3390/v8120322 121FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined" exact="chloroquine" post="and ribavirin treatment does not prevent death in a"/>
  <result pre="zika virus infection in different cell modelsViruses8201610.3390/v8120322 121FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined chloroquine and" exact="ribavirin" post="treatment does not prevent death in a hamster model"/>
  <result pre="potent inhibitor of SARS coronavirus infection and spreadVirol. J.2200510.1186/1743-422X-2-69 125GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 128SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
  <result pre="other developing countriesDiabetes Metab. Syndr. Clin. Res. Rev.202010.1016/j.dsx.2020.03.011 129MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
  <result pre="of the RECOVERY Trial, No clinical benefit from use of" exact="hydroxychloroquine" post="in hospitalised patients with COVID-19, Recover. Trial. (2020). https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-co"/>
  <result pre="2020). 132Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for" exact="Chloroquine" post="and Hydroxychloroquine | FDA, (n.d.). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (accessed June 20,"/>
  <result pre="(COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and" exact="Hydroxychloroquine" post="| FDA, (n.d.). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (accessed June 20, 2020). 133Al-BariM.A.A.Targeting"/>
  <result pre="(n.d.). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (accessed June 20, 2020). 133Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
  <result pre="Sierra Vega, J.J. GarcÃ­a Vieitez, The pharmacokinetics and interactions of" exact="ivermectin" post="in humans - A mini-review, AAPS J. 10 (2008)"/>
  <result pre="replication of HIV-1 and dengue virusBiochem. J.443201285185610.1042/BJ2012015022417684 139CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Res.178202010478710.1016/j.antiviral.2020.104787 140Al-HoraniR.A.DesaiU.R.Recent"/>
  <result pre="for the treatment of fibrinolysis-related disordersMed. Res. Rev.3420141168121610.1002/med.2131524659483 141YamamotoM.MatsuyamaS.LiX.TakedaM.KawaguchiY.InoueJ.I.MatsudaZ.Identification of" exact="nafamostat" post="as a potent inhibitor of middle east respiratory syndrome"/>
  <result pre="- PubChem, (n.d.). https://pubchem.ncbi.nlm.nih.gov/compound/Darunavir#section=Drug-Warnings (accessed June 22, 2020). 169F.S. Structures," exact="Azithromycin" post="_ C38H72N2O12 - PubChem, (2020). https://pubchem.ncbi.nlm.nih.gov/compound/Azithromycin (accessed June 22,"/>
  <result pre="(2020). https://pubchem.ncbi.nlm.nih.gov/compound/Azithromycin (accessed June 22, 2020). 170JuurlinkD.N.Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infectionCMAJ1922020E450E45310.1503/cmaj.20052832269021 171Nafamostat"/>
  <result pre="(accessed June 22, 2020). 170JuurlinkD.N.Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infectionCMAJ1922020E450E45310.1503/cmaj.20052832269021 171Nafamostat | C19H17N5O2"/>
 </snippets>
</snippetsTree>
